Fiscal Year Ending March 2026 (FY2025) Financial Results Briefing

Performance Overview

Net sales for the fiscal year ending March 2026 reached 97,406 million yen, an increase of 10.3% compared to the same period last year, setting a record high. Pharmaceuticals business grew by 3.5%, while other business segments increased by 49.3%. Operating loss was 2,927 million yen; however, gains from sale of investment securities were recorded as extraordinary income, leading to net income of 13,779 million yen (up 15.2%). R&D expenses surged by 74.7% to 22,521 million yen, contributed by technology licensing agreements for thyroid eye disease treatments and the start of clinical trials for new products.

Segment Performance and Future Outlook

Pharmaceutical segment net sales amounted to 77,950 million yen (up 3.5%), driven by growth in domestic products such as Beova, Tabneos, Korsba, and Tabaris. Overseas license revenues increased through export sales, despite a decline in licensing fees due to a reactionary decrease. Other businesses saw significant increases due to higher orders related to GIGA School initiatives in the information services sector. For FY2027, net sales are projected to be 95,700 million yen (down 1.8%), with operating income of 4,400 million yen and net income of 14,500 million yen. R&D expenses are expected to decrease to 16,500 million yen, but the company will continue advancing clinical development themes.